Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather E Stefanski

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Blood Advances|July 14, 2026
Infection Burden in Mismatched Unrelated Donor Hematopoietic Cell Transplantation: Results from the ACCESS TrialJeffery J Auletta, Joseph Stanek, Stephanie Bo-Subait, et al.
Blood Advances|October 6, 2025
Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamideDipenkumar Modi, Yosra M Aljawai, Todd E DeFor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated DonorsBrian C Shaffer, Mahasweta Gooptu, Todd E DeFor, et al.
The Journal of Clinical Investigation|April 5, 2017
Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host diseaseDanny W Bruce, Heather E Stefanski, Benjamin G Vincent, et al.
Bone Marrow Transplantation|March 5, 2024
Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMTAnna Sureda, Paul A Carpenter, Andrea Bacigalupo, et al.
Bone Marrow Transplantation|June 21, 2024
Correction: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMTAnna Sureda, Paul A Carpenter, Andrea Bacigalupo, et al.
Blood Cancer Discovery|January 12, 2022
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic LeukemiaMichael A Pulsipher, Xia Han, Shannon L Maude, et al.
The Lancet. Haematology|July 28, 2022
Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issuesNina Worel, Mahmoud Aljurf, Chloe Anthias, et al.
The Lancet. Oncology|October 14, 2019
Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trialTheodore W Laetsch, Gary Douglas Myers, André Baruchel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2022
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA TrialTheodore W Laetsch, Shannon L Maude, Susana Rives, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Blood Advances|July 14, 2026
Infection Burden in Mismatched Unrelated Donor Hematopoietic Cell Transplantation: Results from the ACCESS TrialJeffery J Auletta, Joseph Stanek, Stephanie Bo-Subait, et al.
Blood Advances|October 6, 2025
Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamideDipenkumar Modi, Yosra M Aljawai, Todd E DeFor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated DonorsBrian C Shaffer, Mahasweta Gooptu, Todd E DeFor, et al.
The Journal of Clinical Investigation|April 5, 2017
Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host diseaseDanny W Bruce, Heather E Stefanski, Benjamin G Vincent, et al.
Bone Marrow Transplantation|March 5, 2024
Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMTAnna Sureda, Paul A Carpenter, Andrea Bacigalupo, et al.
Bone Marrow Transplantation|June 21, 2024
Correction: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMTAnna Sureda, Paul A Carpenter, Andrea Bacigalupo, et al.
Blood Cancer Discovery|January 12, 2022
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic LeukemiaMichael A Pulsipher, Xia Han, Shannon L Maude, et al.
The Lancet. Haematology|July 28, 2022
Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issuesNina Worel, Mahmoud Aljurf, Chloe Anthias, et al.
The Lancet. Oncology|October 14, 2019
Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trialTheodore W Laetsch, Gary Douglas Myers, André Baruchel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2022
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA TrialTheodore W Laetsch, Shannon L Maude, Susana Rives, et al.
Pageof 6